Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, multicenter, randomized controlled trial designed to evaluate whether short-term blinatumomab intensification before allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival outcomes in adults with high-risk BCR::ABL1-negative B-cell acute lymphoblastic leukemia (B-ALL) who have achieved measurable residual disease (MRD) negativity. Blinatumomab, a CD19/CD3 bispecific T-cell engager, has shown promising efficacy in eradicating MRD and prolonging survival in B-ALL patients. In this study, eligible participants will be randomly assigned to receive either short-term blinatumomab consolidation prior to allo-HSCT or proceed directly to allo-HSCT. The primary endpoint is relapse-free survival (RFS). This study aims to optimize treatment strategies and improve long-term outcomes for patients with high-risk BCR::ABL1-negative B-ALL.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza białaczki limfoblastycznej B-komórkowej według klasyfikacji WHO 2022
- •Wiek 18-65 lat
- •Białaczka zaliczana do grupy wysokiego ryzyka ze względu na cechy genetyczne lub kliniczne
- •Białaczka CD19-dodatnia i bez mutacji BCR-ABL1
- •Całkowita remisja (brak widocznych znaków choroby) po początkowym leczeniu
- •Brak resztek choroby potwierdzone badaniem laboratoryjnym
- •Dostępny dawca szpiku (spokrewniony lub niespokrewniony)
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG 0-2)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 65 Years
- Last updated (source)
- September 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
Trial contact
Hengwei Wu Attending, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.